Literature DB >> 30925534

Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure.

Santiago Avila-Rios1, Jonathan M Carlson2, Mina John3, Simon Mallal3,4, Zabrina L Brumme5,6.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize recent advances in our understanding of HIV adaptation to human leukocyte antigen (HLA)-associated immune pressures and its relevance to HIV prevention and cure research. RECENT
FINDINGS: Recent research has confirmed that HLA is a major driver of individual and population-level HIV evolution, that HIV strains are adapting to the immunogenetic profiles of the different human ethnic groups in which they circulate, and that HIV adaptation has substantial clinical and immunologic consequences. As such, adaptation represents a major challenge to HIV prevention and cure. At the same time, there are opportunities: Studies of HIV adaptation are revealing why certain HLA alleles are protective in some populations and not others; they are identifying immunogenic viral epitopes that harbor high mutational barriers to escape, and they may help illuminate novel, vaccine-relevant HIV epitopes in regions where circulating adaptation is extensive. Elucidation of HLA-driven adapted and nonadapted viral forms in different human populations and HIV subtypes also renders 'personalized' immunogen selection, as a component of HIV cure strategies, conceptually feasible.
SUMMARY: Though adaptation represents a major challenge to HIV prevention and cure, achieving an in-depth understanding of this phenomenon can help move the design of such strategies forward.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30925534      PMCID: PMC6457261          DOI: 10.1097/COH.0000000000000541

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  140 in total

1.  Distinct HIV-1 escape patterns selected by cytotoxic T cells with identical epitope specificity.

Authors:  Yuichi Yagita; Nozomi Kuse; Kimiko Kuroki; Hiroyuki Gatanaga; Jonathan M Carlson; Takayuki Chikata; Zabrina L Brumme; Hayato Murakoshi; Tomohiro Akahoshi; Nico Pfeifer; Simon Mallal; Mina John; Toyoyuki Ose; Haruki Matsubara; Ryo Kanda; Yuko Fukunaga; Kazutaka Honda; Yuka Kawashima; Yasuo Ariumi; Shinichi Oka; Katsumi Maenaka; Masafumi Takiguchi
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

2.  Increased frequency of HLA A2/DR4 and A2/DR8 haplotypes in young saskatchewan aboriginal people with diabetic end-stage renal disease.

Authors:  Roland Dyck; Clara Bohm; Helena Klomp
Journal:  Am J Nephrol       Date:  2003-04-16       Impact factor: 3.754

3.  Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.

Authors:  Joshua T Herbeck; Viktor Müller; Brandon S Maust; Bruno Ledergerber; Carlo Torti; Simona Di Giambenedetto; Luuk Gras; Huldrych F Günthard; Lisa P Jacobson; James I Mullins; Geoffrey S Gottlieb
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

4.  Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load.

Authors:  Samuel Alizon; Viktor von Wyl; Tanja Stadler; Roger D Kouyos; Sabine Yerly; Bernard Hirschel; Jürg Böni; Cyril Shah; Thomas Klimkait; Hansjakob Furrer; Andri Rauch; Pietro L Vernazza; Enos Bernasconi; Manuel Battegay; Philippe Bürgisser; Amalio Telenti; Huldrych F Günthard; Sebastian Bonhoeffer
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

5.  Selective induction of CTL helper rather than killer activity by natural epitope variants promotes dendritic cell-mediated HIV-1 dissemination.

Authors:  Robbie B Mailliard; Kellie N Smith; Ronald J Fecek; Giovanna Rappocciolo; Eduardo J M Nascimento; Ernesto T Marques; Simon C Watkins; James I Mullins; Charles R Rinaldo
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

6.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Authors:  Dan H Barouch; Frank L Tomaka; Frank Wegmann; Daniel J Stieh; Galit Alter; Merlin L Robb; Nelson L Michael; Lauren Peter; Joseph P Nkolola; Erica N Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E Stephenson; Wenjun Li; Bette Korber; Georgia D Tomaras; David C Montefiori; Glenda Gray; Nicole Frahm; M Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G Pau; Hanneke Schuitemaker
Journal:  Lancet       Date:  2018-07-06       Impact factor: 79.321

7.  Adaptation of HIV-1 to human leukocyte antigen class I.

Authors:  Yuka Kawashima; Katja Pfafferott; John Frater; Philippa Matthews; Rebecca Payne; Marylyn Addo; Hiroyuki Gatanaga; Mamoru Fujiwara; Atsuko Hachiya; Hirokazu Koizumi; Nozomi Kuse; Shinichi Oka; Anna Duda; Andrew Prendergast; Hayley Crawford; Alasdair Leslie; Zabrina Brumme; Chanson Brumme; Todd Allen; Christian Brander; Richard Kaslow; James Tang; Eric Hunter; Susan Allen; Joseph Mulenga; Songee Branch; Tim Roach; Mina John; Simon Mallal; Anthony Ogwu; Roger Shapiro; Julia G Prado; Sarah Fidler; Jonathan Weber; Oliver G Pybus; Paul Klenerman; Thumbi Ndung'u; Rodney Phillips; David Heckerman; P Richard Harrigan; Bruce D Walker; Masafumi Takiguchi; Philip Goulder
Journal:  Nature       Date:  2009-02-25       Impact factor: 49.962

8.  Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine.

Authors:  James Theiler; Hyejin Yoon; Karina Yusim; Louis J Picker; Klaus Fruh; Bette Korber
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

9.  HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses.

Authors:  Nathan Erdmann; Victor Y Du; Jonathan Carlson; Malinda Schaefer; Alexander Jureka; Sarah Sterrett; Ling Yue; Dario Dilernia; Shabir Lakhi; Jianming Tang; John Sidney; Jill Gilmour; Susan Allen; Eric Hunter; Sonya Heath; Anju Bansal; Paul A Goepfert
Journal:  PLoS Pathog       Date:  2015-08-24       Impact factor: 6.823

10.  Impact of pre-adapted HIV transmission.

Authors:  Jonathan M Carlson; Victor Y Du; Nico Pfeifer; Anju Bansal; Vincent Y F Tan; Karen Power; Chanson J Brumme; Anat Kreimer; Charles E DeZiel; Nicolo Fusi; Malinda Schaefer; Mark A Brockman; Jill Gilmour; Matt A Price; William Kilembe; Richard Haubrich; Mina John; Simon Mallal; Roger Shapiro; John Frater; P Richard Harrigan; Thumbi Ndung'u; Susan Allen; David Heckerman; John Sidney; Todd M Allen; Philip J R Goulder; Zabrina L Brumme; Eric Hunter; Paul A Goepfert
Journal:  Nat Med       Date:  2016-05-16       Impact factor: 53.440

View more
  4 in total

1.  Have Cells Harboring the HIV Reservoir Been Immunoedited?

Authors:  Szu-Han Huang; Chase D McCann; Talia M Mota; Chao Wang; Steven M Lipkin; R Brad Jones
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

Review 2.  Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.

Authors:  Geetha Mylvaganam; Adrienne G Yanez; Marcela Maus; Bruce D Walker
Journal:  Front Immunol       Date:  2019-09-10       Impact factor: 7.561

Review 3.  The Cynomolgus Macaque MHC Polymorphism in Experimental Medicine.

Authors:  Takashi Shiina; Antoine Blancher
Journal:  Cells       Date:  2019-08-26       Impact factor: 6.600

4.  Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection.

Authors:  Camilla Muccini; Monica Guffanti; Vincenzo Spagnuolo; Massimo Cernuschi; Laura Galli; Alba Bigoloni; Andrea Galli; Andrea Poli; Sara Racca; Antonella Castagna
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.